Tirzepatide (20 mg vial)

Tirzepatide (20 mg vial)

Primary use: Weight loss and type 2 diabetes management

Mechanism / class: Dual incretin agonist — GLP-1 receptor + GIP receptor

Key effects:

• Suppresses appetite via central GLP-1 signaling

• Enhances insulin secretion in a glucose-dependent manner

• Improves insulin sensitivity (GIP pathway contribution)

• Produces substantial total body weight reduction

• Reduces HbA1c and post-prandial glucose spikes

Clinical distinction:
Combines GLP-1 appetite suppression with GIP-mediated metabolic enhancement, producing greater weight loss and glycemic control than GLP-1–only agents in clinical trials; does not activate glucagon receptors (unlike retatrutide).

Tirzepatide is supplied strictly for research and development purposes only. Not for human or veterinary consumption.